Concepedia

Luz Hammershaimb

LH

16

Publications

2.3K

Citations

13

H-Index

1996

Active since

Affiliations

National Cancer Institute(Current)

University of Pittsburgh

UPMC Hillman Cancer Center

Radboud University Medical Center

Oregon Health & Science University

Luz Hammershaimb is an author at National Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

1996–2010

16

Publications

16

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al. · Journal of Clinical Oncology · 2000 · 1.4K citations

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α<sub>v</sub>β<sub>3</sub>, ± dacarbazine in patients with stage IV metastatic melanoma

Peter Hersey, Jeffrey A. Sosman, Steven O’Day et al. · Cancer · 2010 · 186 citations · Full text

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens C. Eickhoff, Fred T. Lee et al. · Clinical Cancer Research · 2005 · 157 citations

, , +15

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.

F. Moffat, Carl Pinsky, Luz Hammershaimb et al. · Journal of Clinical Oncology · 1996 · 126 citations

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Catherine Delbaldo, Éric Raymond, Karina Vera et al. · Investigational New Drugs · 2007 · 100 citations

, , +7

Rows per page

1–5 of 16